340B hospitals are asking CMS to use its regulatory flexibility to delay a proposed Medicare survey of 340B hospitals’ drug acquisition costs and to suspend a controversial Part B pay cut for 340B drugs during the COVID-19 pandemic, among other steps. CMS cut Medicare pay for 340B drugs by almost 30% starting in 2018, but a district court said that move went beyond the agency’s authority. CMS said in a February notice that in the event the United States District...